| Literature DB >> 29104501 |
Chanchal Mandal1, Debasish Halder1, Kyoung Hwa Jung1,2, Young Gyu Chai1,3.
Abstract
Ethanol is well known for its teratogenic effects during fetal development. Maternal alcohol consumption allows the developing fetus to experience the detrimental effects of alcohol exposure. Alcohol-mediated teratogenic effects can vary based on the dosage and the length of exposure. The specific mechanism of action behind this teratogenic effect is still unknown. Previous reports demonstrated that alcohol participates in epigenetic alterations, especially histone modifications during fetal development. Additional research is necessary to understand the correlation between major epigenetic events and alcohol-mediated teratogenesis such as that observed in fetal alcohol spectrum disorder (FASD). Here, we attempted to collect all the available information concerning alcohol-mediated histone modifications during gestational fetal development. We hope that this review will aid researchers to further examine the issues associated with ethanol exposure.Entities:
Keywords: Alcohol; Epigenetics; FAS; FASD; Histone modifications.; Teratogenic effects
Mesh:
Year: 2017 PMID: 29104501 PMCID: PMC5666325 DOI: 10.7150/ijbs.21047
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1Alcohol metabolism in the body. Following alcohol consumption, most is absorbed by the small intestine and the stomach. Through circulation, alcohol quickly reaches the liver, where it is broken down. Two major pathways are involved in ethanol metabolism: 1) the oxidative pathway, and 2) the non-oxidative pathway. 1) In the oxidative pathway, alcohol is metabolized to acetaldehyde by cytosolic alcohol dehydrogenase (ADH). If a large amount of ethanol is present, cytochrome P450 IIE1 (CYP2E1) in the endoplasmic reticulum may also be involved in alcohol metabolism. A minor oxidative reaction also occurs in the peroxisomes, where the catalase enzyme is responsible for alcohol metabolism. Consequently, the intermediate metabolite acetaldehyde is metabolized by aldehyde dehydrogenase 2 (ALDH2) to form acetate in the mitochondria. 2) Two enzymes are involved in the non-oxidative pathway. In the presence of fatty acids, ethanol is metabolized to fatty acid ethyl ester (FAEE) by FAEE synthase. A phosphatidylcholine-specific enzyme named phospholipase D is involved in producing phosphatidylethanol from ethanol. The products of both the oxidative and non-oxidative pathways are quickly released into circulation, through which ethanol metabolites affect the peripheral organs. EtOH, ethanol; CH3CHO, acetaldehyde; H2O2, hydrogen peroxide; NAD/NADH, nicotinamide adenine dinucleotide; ROS, reactive oxygen species.
Figure 2Correlation between alcohol metabolites and histone modification. In the liver, ethanol is converted to acetate through the action of different metabolic enzymes. Increased levels of acetate quickly escape the liver and reach the blood stream and other parts of the body. In mitochondria, acetate is transformed to acetyl-CoA by the enzyme acyl-CoA synthetase short-chain family member 2 (ACSS2). The resulting acetyl CoA then enters the Krebs cycle and combines with oxaloacetate to form citrate. Citrate is either oxidized within the Krebs cycle or exported to the cytoplasm, where it subjected to cleavage into acetyl-CoA by the enzyme ATP-citrate lyase (ACL). Acetyl-CoA is the sole donor of acetyl groups to acetylate histone proteins, either by influencing acetyltransferase catalytic activity or non-enzymatically. An elevated level of acetate from alcohol metabolism also causes an increase in the NADH:NAD+ ratio. An increased NADH:NAD+ ratio causes functional impairment of NAD+-dependent enzymes and results in histone deacetylation. Alcohol-mediated folate deficiency reduces S-adenosylmethionine (SAM) level and the SAM to S-adenosyl homocysteine (SAH) ratio as well as increases the SAH concentration, which in turns inhibits histone methyl transferase (HMT). Additionally, the intermediate products of the Krebs cycle, fumarate and succinate, act as inhibitors of Jumonji-C domain-containing histone demethylases (JHDMs). AMP-activated protein kinase (AMPK) is involved in sensing ATP fluctuation in cells and becomes activated to phosphorylate histone proteins. Formation of energetic stress causes the activation of AMPK and leads to histone phosphorylation. H2O2: Hydrogen peroxide; H2O: Water; ADH: Alcohol dehydrogenase; NAD/NADH: Nicotinamide adenine dinucleotide; CYP2E1: Cytochrome P450 IIE1; ALDH: Aldehyde dehydrogenase; CoA-SH: CoA synthase; KAT: Lysine acetyltransferase; SIRT: Sirtuin; FA: Folic acid; THF: Tetrahydrofolate; MTHF: methylene tetrahydrofolate; MS: Methionine synthase; MAT: Methionine adenyltransferase; GDP: Guanosine diphosphate; GTP: Guanosine triphosphate; ATP: Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate.
Summary of alcohol-mediated histone modifications in utero.
| Model organism | Pattern of alcohol exposure | Sampling | Status of histone signature | Reference |
|---|---|---|---|---|
| Mouse | 25% ethanol (3.75 g/kg) | E13.5 lung | Induction of H3K9/18ac | |
| Cardiac progenitor cells | 200 mM | Cell culture exposed for 24 h | Induction of H3K9ac | |
| Rat | 4 hr/day in the inhalation chamber (vapor of ethanol) | P8 brain (cerebellum) | Reduction of H3 and H4 acetylation. | |
| Cardiac progenitor cells | 200 mM | Cell culture exposed for 24 h | Elevation of H3K9ac and the expression of | |
| Rat | ethanol in liquid diet | P60-P80 of each generation (F1, F2 and F3); brain | Reduction of H3K4me2, H3K4me3 and H3K9ace marks; induction of H3K9me2 mark. | |
| Rat | 6.7% v/v (in liquid diet) equivalent to ∼120-150 mg/dl in blood | P60-65 brain | Induction of H3K9me2 mark; deduction of H3K4me2, H3K4me3, H3K9ac, pH3S10 marks. | |
| Mouse | 1.0 or 2.5 g/kg (subcutaneous injection) | P7 brain | Elevation of | |
| Mouse (fetal cerebral cortical neuroepithelial stem cells) | 320 mg/dL (70mM) | Neurosphere Culture exposed for 5 days | Reduction of H3K4me3 mark at | |
| Mouse | 10 μl/g/d (56% alcohol) by gavage | E11.5, E14.5, E17.5, and E18.5 fetal heart | Induction of HAT activity and H3K9ac signature. | |
| Mouse | 5 ml/kg (56% v/v) intragastrically | E14.5 and E16.5 fetal heart; P0.5 and P7 neonatal heart | Induction of HAT activity and binding of P300, CBP, PCAF and SRC1 to the | |
| Mouse | 1.0 g/kg (subcutaneous injection) | P7 brain | Induction of H3K14ac at G9a exon1. | |
| Mouse | 2.5 g/kg (subcutaneous injection) | P7 brain | Elevation of H4K8ac and reduction of H3K9me2 at exon1 of the | |
| Mouse | 6 g/kg/d (56%) intragastrically | E14.5 fetal heart | Elevation of H3K14ac mark and the expression of | |
| Mouse | 2.5 g/kg (subcutaneous injection) | P7 brain | Reduction of H3K9me2 mark. | |
| Rat (Fetal heart-derived cell line) | 200 mM | H9c2 cell culture | Induction of H3 acetylation level. | |
| Mouse | 5 ml/kg (56% v/v) intragastrically | E14.5 and E16.5 fetal heart; P0.5 and P7 neonatal heart | Hyperacetylation of histone H3K9 on the | |
| Rat | 6.7% v/v (in liquid diet) equivalent to 120-150 mg/dl in blood | P60-P90 pituitary gland | Elevation of pituitary mRNA levels of histone modifying genes ( | |
| Mouse | 10% v/v in drinking water | P87 hippocampus | Enrichment of histone H3K4me3 mark at the | |
| Mouse | 2.9 g/kg (intraperitoneal injection) | E17 forebrain | Elevation of H3K9me2, H3K9ace marks and reduction of H3K27me3 mark. | |
| Human dental pulp stem cells (DPSCs) | 20 or 50 mM (both acute and chronic exposure) | DPSC cell culture | Suppression of |
Figure 3Summary of alcohol-mediated histone modifications Gestational alcohol exposure causes epigenetic alteration in the developing fetus. Many histone marks are altered by alcohol during fetal development. Research suggests that alcohol can alter the expression level of several important epigenetic modulators that contribute to the alteration of histone marks. Current knowledge about alcohol toxicity indicates that it is able to affect acetylation/deacetylation, methylation/demethylation and phosphorylation of histone proteins. However, the correlation of these changes with the FASD phenotype remains unknown.